Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 11/20 | 0.62 |
| ▸ | MAOA | P21397 | 11/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | PPIA | P62937 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30132801 | 1.00 | MAOB (0.62) | MAOBMAOAALDH1A1PPIALMNA | |
| SCHEMBL25386333 | 0.91 | MAOB (0.54) | MAOBMAOAALDH1A1PPIALMNA | |
| SCHEMBL365201 | 0.84 | MAPT (0.61) | MAOBMAOAALDH1A1PPIALMNA | |
| SCHEMBL31621082 | 0.84 | MAPT (0.61) | MAOBMAOAALDH1A1PPIALMNA | |
| SCHEMBL31470976 | 0.84 | MAOB (0.61) | MAOBMAOAALDH1A1PPIALMNA | |
| SCHEMBL25386767 | 0.84 | MAOB (0.61) | MAOBMAOAALDH1A1PPIALMNA | |
| SCHEMBL13932290 | 0.81 | PARP1 (0.50) | MAOBMAOAALDH1A1PPIAACHE | |
| SCHEMBL10555531 | 0.77 | MAPK14 (0.60) | — | |
| SCHEMBL24102359 | 0.76 | MAOA (0.55) | MAOBMAOALMNAGAAMAPT | |
| SCHEMBL2257538 | 0.76 | MAOA (0.59) | MAOBMAOAALDH1A1PPIALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120157657-A | Phthalazinone compound containing piperazinone, preparation method, pharmaceutical composition and application thereof | 中国医学科学院药物研究所 | 2025-06-17 | — | — | CN | disclosed |
| EP-4143182-B1 | NOVEL COMPOUNDS USEFUL AS POLY(ADP-RIBOSE) POLYMERASE (PARP) INHIBITORS | RHIZEN PHARMACEUTICALS AG (CH) | 2024-12-11 | — | — | EP | disclosed |
| WO-2023139536-A1 | (4-PIPERAZIN-1YL)-4-ALKYL-PHTHALAZIN-1(2H)-ONE COMPOUNDS AS PARP7 INHIBITORS | RHIZEN PHARMACEUTICALS AG (CH) | 2023-07-27 | — | — | WO | disclosed |
| US-20230234938-A1 | NOVEL COMPOUNDS USEFUL AS POLY(ADP-RIBOSE) POLYMERASE (PARP) INHIBITORS | RHIZEN PHARMACEUTICALS AG (CH) | 2023-07-27 | — | — | US | disclosed |
| EP-4143182-A1 | NOVEL COMPOUNDS USEFUL AS POLY(ADP-RIBOSE) POLYMERASE (PARP) INHIBITORS | Rhizen Pharmaceuticals AG (CH) | 2023-03-08 | — | — | EP | disclosed |
| CN-115485271-A | Novel compounds as inhibitors of poly (ADP-ribose) polymerase (PARP) | 理森制药股份公司 | 2022-12-16 | — | — | CN | disclosed |
| WO-2021220120-A1 | NOVEL COMPOUNDS USEFUL AS POLY(ADP-RIBOSE) POLYMERASE (PARP) INHIBITORS | RHIZEN PHARMACEUTICALS AG (CH) | 2021-11-04 | — | — | WO | disclosed |
| EP-2582668-B1 | CARBOLINE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-01-13 | — | — | EP | disclosed |
| EP-2582668-B1 | CARBOLINE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-01-13 | — | — | EP | disclosed |
| US-8604221-B2 | Production method of halogen-substituted phthalide | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2013-12-10 | — | — | US | disclosed |
| WO-2011159857-A1 | CARBOLINE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-12-22 | — | — | WO | disclosed |
| EP-1778676-B1 | HYDANTOIN DERIVATIVES FOR THE TREATMENT OF INFLAMMATORY DISORDERS | SCHERING CORP (US) | 2010-08-25 | — | — | EP | disclosed |
| CN-100430390-C | Water-soluble triazole antifungal agents | SANKYO CO (JP) | 2008-11-05 | — | — | CN | disclosed |
| EP-1362856-B1 | WATER-SOLUBLE TRIAZOLE FUNGICIDE | DAIICHI SANKYO CO LTD (JP) | 2008-09-10 | — | — | EP | disclosed |
| CN-100349569-C | Water-soluble triazole fungicide | SANKYO CO (JP) | 2007-11-21 | — | — | CN | disclosed |
| US-7230023-B2 | Water-soluble triazole fungicide | SANKYO COMPANY, LIMITED (JP) | 2007-06-12 | — | — | US | disclosed |
| CN-1720913-A | Water-soluble triazole fungicide | SANKYO CO (JP) | 2006-01-18 | — | — | CN | disclosed |
| US-20040198790-A1 | Water-soluble triazole fungicide | SANKYO COMPANY, LIMITED (JP) | 2004-10-07 | — | — | US | disclosed |
| CN-1503795-A | Water-soluble triazole antifungal agents | ������������ʽ���� | 2004-06-09 | — | — | CN | disclosed |
| EP-1362856-A1 | WATER-SOLUBLE TRIAZOLE FUNGICIDE | Sankyo Company, Limited (JP) | 2003-11-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040198790-A1 | Water-soluble triazole fungicide | ERG28, CYP51A1, XDH | MAOB 1364/4885MAOA 1236/4885ALDH1A1 1619/4885 |
| US-20230234938-A1 | NOVEL COMPOUNDS USEFUL AS POLY(ADP-RIBOSE) POLYMERASE (PARP) INHIBITORS | PARP1, PARP2, PARP3 | MAOB 1128/4885MAOA 1200/4885ALDH1A1 426/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.